SCHEMBL716282

SCHEMBL716282

Cc1c(Br)c2ccccc2n1C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.48
CHRM4 P08173 1/20 0.48
CHRM1 P11229 1/20 0.48
CHRM3 P20309 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.44
MAPT P10636 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
POLB P06746 1/20 0.41
CCNB2 O95067 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
GSK3B P49841 1/20 0.41
CCNB3 Q8WWL7 1/20 0.41
NR1H2 P55055 8/20 0.41
BCHE P06276 1/20 0.39
NR1H3 Q13133 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29374715 1.00 CHRM2 (0.48) CHRM2CHRM4CHRM1CHRM3L3MBTL1
SCHEMBL18157744 0.83 GABRP (0.45) L3MBTL1MAPTKDM4EALDH1A1MEN1
SCHEMBL13696680 0.82 CHRM2 (0.59) CHRM2CHRM4CHRM1CHRM3L3MBTL1
SCHEMBL30022454 0.82 CHRM2 (0.59) CHRM2CHRM4CHRM1CHRM3L3MBTL1
SCHEMBL27691112 0.82 CHRM2 (0.48) CHRM2CHRM4CHRM1CHRM3L3MBTL1
SCHEMBL28984623 0.82 CHRM2 (0.48) CHRM2CHRM4CHRM1CHRM3L3MBTL1
SCHEMBL19418900 0.82 CHRM2 (0.48) CHRM2CHRM4CHRM1CHRM3L3MBTL1
SCHEMBL23090046 0.82 CHRM2 (0.48) CHRM2CHRM4CHRM1CHRM3L3MBTL1
SCHEMBL29736738 0.82 CHRM2 (0.48) CHRM2CHRM4CHRM1CHRM3L3MBTL1
SCHEMBL23104799 0.82 CHRM2 (0.45) CHRM2CHRM4CHRM1CHRM3L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2026-03-12 US disclosed
US-20260022142-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2026-01-22 US disclosed
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2025-08-07 US disclosed
US-20250179046-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS ZOETIS SERVICES LLC 2025-06-05 US disclosed
US-20250163104-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL MYERS SQUIBB CO (US) 2025-05-22 US disclosed
US-12240827-B2 Serotonin 5-HT2B inhibitory compounds ZOETIS SERVICES LLC (US) 2025-03-04 US disclosed
US-20240409585-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2024-12-12 US disclosed
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES PEPTIDREAM INC (JP) 2024-12-05 US disclosed
CN-119013287-A Macrocyclic immunomodulators 百时美施贵宝公司 2024-11-22 CN disclosed
US-20240360178-A1 MACROCYCLIC IMMUNOMODULATORS BRISTOL-MYERS SQUIBB COMPANY 2024-10-31 US disclosed
US-7897781-B2 Cold menthol receptor-1 antagonists JANSSEN PHARMACEUTICA NV (BE) 2011-03-01 US disclosed
US-7897781-B2 Cold menthol receptor-1 antagonists JANSSEN PHARMACEUTICA NV (BE) 2011-03-01 US disclosed
WO-2010136491-A1 BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE F. HOFFMANN-LA ROCHE AG (CH) 2010-12-02 WO disclosed
US-20100305084-A1 BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE HOFFMAN-LA ROCHE INC. 2010-12-02 US disclosed
US-20080287398-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-11-20 US disclosed
US-20080287398-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-11-20 US disclosed
US-20080287398-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-11-20 US disclosed
US-20080027029-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-31 US disclosed
US-20080027029-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-31 US disclosed
US-20080027029-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS JANSSEN PHARMACEUTICA N.V. (BE) 2008-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12240827-B2 Serotonin 5-HT2B inhibitory compounds HTR2B, HTR1B, HTR5A CHRM2 524/4885CHRM4 298/4885CHRM1 639/4885
US-20080027029-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS TRPM8, TRPM5, TRPM7 CHRM2 349/4885CHRM4 365/4885CHRM1 235/4885
US-20250179046-A1 SEROTONIN 5-HT2B INHIBITORY COMPOUNDS HTR2B, HTR1B, HTR5A CHRM2 524/4885CHRM4 298/4885CHRM1 639/4885
US-20250163104-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 CHRM2 4265/4885CHRM4 4138/4885CHRM1 4182/4885
US-20100305084-A1 BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE PI4K2B, PIK3CA, PIK3R2 CHRM2 1207/4885CHRM4 2208/4885CHRM1 1348/4885
US-20260022142-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 CHRM2 1026/4885CHRM4 1730/4885CHRM1 618/4885
US-20260070945-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1, PDCD1LG2 CHRM2 1448/4885CHRM4 2171/4885CHRM1 781/4885
US-20240360178-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 CHRM2 3687/4885CHRM4 3781/4885CHRM1 3367/4885
US-20240409585-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 CHRM2 3645/4885CHRM4 3747/4885CHRM1 3342/4885
US-20080287398-A1 COLD MENTHOL RECEPTOR-1 ANTAGONISTS TRPM8, TRPM5, TRPM7 CHRM2 349/4885CHRM4 365/4885CHRM1 235/4885
US-20250250299-A1 MACROCYCLIC IMMUNOMODULATORS CD274, PDCD1LG2, PDCD1 CHRM2 3687/4885CHRM4 3781/4885CHRM1 3367/4885
US-20240400499-A1 NOVEL AMINO ACID DERIVATIVES BCAT1, BCAT2, PELP1 CHRM2 4876/4885CHRM4 4881/4885CHRM1 4862/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.